Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.
A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...
Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...
A recent study published in the Journal of Translational Internal Medicine reveals insights into the broader impact of ...
Medically reviewed by Angela Ryan Lee, MD Maintaining heart health is vital to your overall well-being and lowers your risk ...
Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...
Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart disease and the prevention of atheroscl ...
One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.
Each year, over half a million Americans have a stroke, but up to 80% may be preventable with better nutrition, exercise and ...